Preliminary experience with Precipitating Hydrophobic Injectable Liquid (PHIL) in treating cerebral AVMs

45Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective To describe our early experience in treating cerebral arteriovenous malformations (AVMs) with the new Precipitating Hydrophobic Injectable Liquid (PHIL) embolic material. Materials and methods Between June and August 2015 five patients with cerebral AVMs were treated at two tertiary university hospitals. PHIL was used as complementary treatment to Onyx liquid embolic material or as the sole endovascular treatment. Results Five patients (average age 39 years (range 19-73)) with ruptured plexiform AVMs were treated. The group included one patient with Spetzler-Martin grade II AVMs, three grade III, and one grade IV. One grade II and two grade III AVMs were cured. A total of nine pedicles were embolized with an average of two pedicles per session. There were no procedural complications. One patient had a seizure after embolization but a brain CT scan showed no hemorrhage. Conclusions PHIL is a new embolic agent that can be used for the treatment of cerebral AVMs.

Cite

CITATION STYLE

APA

Samaniego, E. A., Kalousek, V., Abdo, G., & Ortega-Gutierrez, S. (2016). Preliminary experience with Precipitating Hydrophobic Injectable Liquid (PHIL) in treating cerebral AVMs. Journal of NeuroInterventional Surgery, 8(12), 1253–1255. https://doi.org/10.1136/neurintsurg-2015-012210

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free